In Multinational Trials, U.S. Often Lags In Efficacy, FDA Analysis Finds
Executive Summary
As drug developers continue to move clinical trials overseas, FDA is keeping a close eye on the differential results that sometimes arise between U.S. and foreign subject populations, potentially affecting the usability of hard-won data for drug applications.